Administrative data

Project reference: DPI2007-66728-C02-01
Title: Closed loop glucose control in diabetes mellitus 1 and critically ill patients – INSULAID2
Participating centers: Coordinated project 
Subproject 1: Universitat Politècnica de València (coordinator)
Subproject 2: Universitat de Girona
Principal investigator: Jorge Bondia (coordinator); Josep Vehí
Funded by: Ministerio de Educación y Ciencia
Duration: 01/10/2007-01/10/2011
Funding awarded: Subproject 1: €195,415.00
Subproject 2: €206,063.00

Project summary

In the 1990s, it was proved that any improvement in glucose control, leads to a reduction of the risk to develop chronic complications associated to diabetes. For this reason, euglycaemia has established as the control objective for patients with diabetes mellitus 1 (DM1). On the other hand, critically ill patients in the Intensive Care Units are subject to a great morbidity and mortality. Last advances in the knowledge of the physiopathology of these patients demonstrate how hyperglycaemia may contribute to their clinical evolution. There exists literature that suggests the importance of achieving euglycaemia in these patients by means of insulin perfusions to reduce mortality. There is thus a great social interest and economic as well in an efficient glucose control.

It is expected that in 4 to 5 years the technology required for an automatic glucose control will be available, being currently continuous glucose monitoring a limiting factor. It is thus of great importance the development of efficient glucose control algorithms, as well as good models of the glucoregulatory system and their validation by means of therapeutic criteria.

In this project the following global objectives are addressed: (1) the implementation of a clinical study for the collection of experimental data to advance in the development of models and their therapeutic validation; (2) the development of advanced control algorithms for closed-loop glucose control in DM1 and critically ill patients. Interval and set-based techniques will be applied to address the problem of intra- and inter-patient variability. Finally, the use of counter-regulatory control signals such as glucagon or glucose, additionally to insulin, will be explored.

People

Hospital Clínico de Valencia

• F. Javier Ampudia

Hospital Francesc de Borja de Gandía

• Paolo Rossetti